RT Journal Article
SR Electronic
T1 Dimethyl fumarate in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.09.23.22280285
DO 10.1101/2022.09.23.22280285
A1 ,
A1 Horby, Peter W
A1 Peto, Leon
A1 Staplin, Natalie
A1 Campbell, Mark
A1 Pessoa-Amorim, Guilherme
A1 Mafham, Marion
A1 Emberson, Jonathan R
A1 Stewart, Richard
A1 Prudon, Benjamin
A1 Uriel, Alison
A1 Green, Christopher A
A1 Dhasmana, Devesh J
A1 Malein, Flora
A1 Majumdar, Jaydip
A1 Collini, Paul
A1 Shurmer, Jack
A1 Yates, Bryan
A1 Baillie, J Kenneth
A1 Buch, Maya H
A1 Day, Jeremy N
A1 Faust, Saul N
A1 Jaki, Thomas
A1 Jeffery, Katie
A1 Juszczak, Edmund
A1 Knight, Marian
A1 Lim, Wei Shen
A1 Montgomery, Alan
A1 Mumford, Andrew
A1 Rowan, Kathryn
A1 Thwaites, Guy
A1 Haynes, Richard
A1 Landray, Martin
YR 2022
UL http://medrxiv.org/content/early/2022/09/25/2022.09.23.22280285.abstract
AB Background Dimethyl fumarate (DMF) is an anti-inflammatory drug that has been proposed as a treatment for patients hospitalised with COVID-19Methods This randomised, controlled, open-label platform trial (Randomised Evaluation of COVID-19 Therapy [RECOVERY]), is assessing multiple possible treatments in patients hospitalised for COVID-19. In this initial assessment of DMF, performed at 27 UK hospitals, eligible and consenting adults were randomly allocated (1:1) to either usual standard of care alone or usual standard of care plus DMF 120mg twice daily for 2 days followed by 240mg twice daily for 8 days, or until discharge if sooner. The primary outcome was clinical status on day 5 measured on a seven-point ordinal scale, assessed using a proportional odds model. Secondary outcomes were time to sustained improvement in clinical status, time to discharge, day 5 peripheral blood oxygenation, day 5 C-reactive protein, and improvement in day 10 clinical status. The trial is registered with ISRCTN (50189673) and clinicaltrials.gov (NCT04381936).Findings Between 2 March 2021 and 18 November 2021, 713 patients were enrolled in the DMF evaluation, of whom 356 were randomly allocated to receive usual care plus DMF, and 357 to usual care alone. 95% of patients were receiving corticosteroids as part of routine care. There was no evidence of a beneficial effect of DMF on clinical status at day 5 (common odds ratio of unfavourable outcome 1.12; 95% CI 0.85-1.46; p=0.42). There was no significant effect of DMF on any secondary outcome. As expected, DMF caused flushing and gastrointestinal symptoms, each in around 6% of patients, but no new adverse effects were identified.Interpretation In adults hospitalised with COVID-19, DMF was not associated with an improvement in clinical outcomes.Funding UK Research and Innovation (Medical Research Council) and National Institute of Health Research (Grant ref: MC_PC_19056).Competing Interest StatementThe authors have declared no competing interest.Clinical TrialThe trial is registered with ISRCTN (50189673) and clinicaltrials.gov (NCT04381936).Clinical Protocols https://www.recoverytrial.net Funding StatementThis study was funded by UK Research and Innovation (Medical Research Council) and National Institute of Health Research (Grant ref: MC_PC_19056).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The trial is conducted in accordance with the Principles of the International Conference on Harmonisation-Good Clinical Practice guidelines and approved by the UK Medicines and Healthcare products Regulatory Agency (MHRA) and the Cambridge East Research Ethics Committee (ref: 20/EE/0101).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors